Wednesday, May 12, 2021

A Short History of Tardive Dyskinesia: 65 Years of Drug-Induced Brain Damage That Rolls...

Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.

An FDA Whistleblower’s Documents: Commerce, Corruption, and Death

In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.

Randomized Controlled Trial Confirms That Antipsychotics Damage the Brain

A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.

The Charade of New Drug Approvals for Schizophrenia

The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.

For People “At Risk for Psychosis,” Antipsychotics Associated with Worse Outcomes

Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.

The BBC, Harrow, and a Public Left in the Dark

The recent report by the BBC on medication-free treatment in Norway, when viewed in conjunction with the media silence on Martin Harrow's latest publication, reveals why the public remains misinformed about the long-term effects of antipsychotics.

Do Antipsychotics Protect Against Early Death? A Review of the Evidence

Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.

The Latest “Breakthrough Therapy”: Expensive New Drugs for Tardive Dyskinesia

The increased prescribing of antipsychotics, which frequently cause a brain injury that manifests as tardive dyskinesia, has provided pharmaceutical companies with a lucrative new market opportunity.

The Case Against Antipsychotics

This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.

Psychiatry Defends Its Antipsychotics: A Case Study of Institutional Corruption

Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.

Very Slow Taper Best for Antipsychotic Discontinuation

An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.
digital antipsychotic

The Rise of the Digital Asylum

The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.

Antipsychotics are Poor Sleep Aids

Research from Australia shows that "remained pervasive" in 70% of a sample of 83 patients medicated with antipsychotics and other medications, and concludes that...
antipsychotic drugs

Antipsychotic Augmentation Increases Risk of Death

A new study finds that adding an antipsychotic to existing antidepressant treatment is associated with a 45% increased risk of early death.

Antipsychotics Associated with Severe COVID-19 and Fatal Outcomes

A new study has found a strong association between antipsychotic drugs and higher rates of severe cases of COVID-19.

Vitamin B6 Effective in Reducing Antipsychotic Induced Akathisia

A recent RCT showed that vitamin B6 is as effective as propranolol for the treatment of akathisia.

Largest Survey of Antipsychotic Experiences Reveals Negative Results

A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.

Keys to Successful Discontinuation of Antipsychotic Medication

Qualitative study finds that both internal resources and systemic factors play a role in antipsychotic discontinuation outcomes.

Greater Exposure to Antipsychotics Associated with Worse Long-Term Outcomes

A new study finds adverse long-term consequences associated with the increased use of antipsychotics in first-episode psychosis.

Anticholinergic Drugs Increase Risk of Cognitive Decline

A new study finds that anticholinergic drugs, like antidepressants and antipsychotics, are associated with mild cognitive decline.

Does Longer Duration of Untreated Psychosis Cause Worse Outcomes?

New research counters the long-held assumption that a longer duration of untreated psychosis is associated with worse outcomes.

Drug Treatment for Borderline Personality Disorder Not Supported By Evidence

New research published in the August issue of Psychiatric Annals evaluates the results of randomized control trials on the use of various psychotropic drugs for patients diagnosed with borderline personality disorder (BPD). Despite the “American Psychiatric Association’s practice guidelines endorsement of SSRIs as first-line therapies for BPD,” the results of the meta-analysis reveal that pharmacotherapy in BPD is “not supported by the current literature,” and “should be avoided whenever possible.”

Review Explores First-Person Experiences of People Taking Antipsychotics

A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.

Relapse in Antipsychotic Drug Trials is Poorly Defined

There is a lack of consensus in the definition of ‘relapse’ across randomized controlled trials of antipsychotic maintenance treatment for schizophrenia and psychosis.

Antipsychotic Trials Show Increasing Placebo Response and Declining Drug Response

A new review of antipsychotic trials conducted over the last 24 years finds that the placebo response rate is steadily increasing, and drug response is decreasing.

Follow Us

19,639FansLike
11,994FollowersFollow
0SubscribersSubscribe